Imugene Ltd (IMU)

Sydney
Currency in AUD
Disclaimer
0.130
+0.005
(+4.00%)
Closed
Day's Range
0.125
0.130
52 wk Range
0.115
0.315
Volume
5,282,211
Prev. Close
0.125
Open
0.13
Day's Range
0.125-0.13
52 wk Range
0.115-0.315
Volume
5,282,211
Average Volume (3m)
12,201,112
1-Year Change
-54.39%
Shares Outstanding
6,423,039,111
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
53.000
Upside +40,669.231%

Imugene Ltd News

Imugene Ltd Analysis

Imugene Ltd Company Profile

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.